TABLE 1

Linezolid AUC0–24, cumulative dose, and days of exposure to linezolid for patients with and without linezolid-related adverse events

Patients#Linezolid AUC0–24 mg·h·L−1p-valueLinezolid cumulative dose mg·kg−1p-valueTotal linezolid exposure daysp-value
Anaemia
 Yes9 (16)158 (117–218)0.299918 (550–1964)0.48097 (52–159)0.768
 No30 (52)128 (98–170)1211 (855–1830)97 (66–150)
Leukopenia+
 Yes5 (9)158 (134–178)0.3141898 (1056–2668)0.194150 (102–352)0.065
 No40 (69)122 (89–171)1046 (739–1813)86 (62–150)
Peripheral  neuropathy
 Yes11 (19)149 (104–185)0.2611829 (1414–2255)0.041159 (120–196)0.003
 No25 (43)107 (91–156)1164 (755–1922)97 (66–147)
Optical  neuropathy
 Yes1 (2)1000.6129970.735890.766
 No48 (83)127 (96–169)1306 (861–1985)105 (67–169)
  • Data are presented as n (%) or median (interquartile range), unless otherwise stated. Linezolid AUC0–24: area under the linezolid time–concentration curve from 0–24 h. Mann–Whitney U test was used to test whether the distribution of parameters was the same across groups with or without anaemia, leukopenia, peripheral neuropathy, and optical neuropathy respectively. #: total number of patients in the study N=58; : anaemia was classified for males as <8.7 mmol·L−1 and for females as <7.5 mmol·L−1; +: leukopenia was classified for both males and females as <4×109·L−1.